Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 949 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Granix Clear all
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00014534
View directory record Official record
Conditions
Bladder Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
285
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Arroyo Grande, California + 197 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Nov 9, 2026, 1:27 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Stem Cells and Filgrastim

NCT00001071
View directory record Official record
Conditions
HIV Infections
Interventions
Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1998
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

NCT02190721
View directory record Official record
Conditions
Neutropenia
Interventions
tbo-filgrastim
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Jackson, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional Results available

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

NCT03096782
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
Interventions
Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

NCT00003173
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Retinoblastoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional Results available

Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy

NCT00258180
View directory record Official record
Conditions
Diarrhea, Gastrointestinal Complications, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, cyclophosphamide
Biological · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

NCT00217503
View directory record Official record
Conditions
Lymphoma
Interventions
bevacizumab, filgrastim, pegfilgrastim, bortezomib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ganciclovir, valganciclovir, zidovudine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional Results available

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00425802
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, rituximab, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, nonmyeloablative allogeneic hematopoietic stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional Results available

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

NCT00490529
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells, Autologous hematopoietic stem cell transplant (HSCT), Rituximab, Standard induction chemotherapy, Cyclophosphamide, Filgrastim
Biological · Procedure · Drug
Lead sponsor
Ronald Levy
Other
Eligibility
21 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Nov 9, 2026, 1:27 PM EST
Not listed Phase 2 Interventional

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

NCT01513603
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitts Leukemia/Lymphoma, Chronic Myelogenous Leukemia
Interventions
CLAG-M
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 1 Interventional

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

NCT00002913
View directory record Official record
Conditions
Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
paclitaxel, cisplatin, topotecan hydrochloride, filgrastim
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 3 Interventional

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

NCT00003313
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
244
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 191 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

NCT00002674
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cytarabine, etoposide, hydroxyurea, mitoxantrone hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
17 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional Results available

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

NCT03301350
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Rockford, Illinois • Madison, Wisconsin • Milwaukee, Wisconsin + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma

NCT00006760
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, ifosfamide, vinorelbine tartrate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
101
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 1Phase 2 Interventional

Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

NCT00004085
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional Results available

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

NCT00671658
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
Rituximab, Cyclophosphamide (CTX), Doxorubicin, Vincristine, Dexamethasone, Methotrexate (MTX), Cytarabine, G-CSF, Mesna, Pegylated asparaginase, Pegfilgrastim, Solumedrol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 1 Interventional

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

NCT00005021
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, carboplatin, paclitaxel, topotecan hydrochloride
Biological · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

NCT00074178
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, pegfilgrastim, cyclophosphamide, cytarabine, dexamethasone, etoposide phosphate, methotrexate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
16 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 2 Interventional

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

NCT00001048
View directory record Official record
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
9
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 9, 2026, 1:27 PM EST
Not listed Not applicable Interventional

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

NCT00295997
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 74 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
San Francisco, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 9, 2026, 1:27 PM EST
Terminated Phase 1 Interventional

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

NCT01258634
View directory record Official record
Conditions
Osteosarcoma, Lung Metastases
Interventions
Dexrazoxane, Doxorubicin, Cisplatin, G-CSF, PEG-filgrastim, Etoposide, Ifosfamide, Mesna, Leucovorin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
2 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 3 Interventional

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

NCT00002611
View directory record Official record
Conditions
Kidney Cancer
Interventions
dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years to 15 Years
Enrollment
3,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Nov 9, 2026, 1:27 PM EST
Completed Phase 1 Interventional

Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma

NCT00070200
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, isotretinoin, melphalan, topotecan hydrochloride, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Nov 9, 2026, 1:27 PM EST